Background: Pneumonias are the most frequent infectious diseases, characterized by a
high prevalence especially among children and adults at risk. The socio-economic impact caused
by Streptococcus pneumoniae is evaluated in terms of morbidity, death rate and hospitalizations.
Objective: The aim of the study was to demonstrate the potential economic advantages by
implementation of an active anti-pneumococcal 13-valent vaccine strategy in Campania region
(Southern Italy) in two different categories of subjects, children (aged 0-12), and adults (aged 50-
79) at risk (hypertension, nephropathies, COPD and heart diseases)
Methods: Vaccination costs were compared with costs necessary to treat avoidable diseases in the
presence and absence of a vaccination program.
Results: Offering anti-pneumococcal 13-valent vaccine to the paediatric population was quantified
as saving one million euros for Italian national health service in two years. In addition, offering
anti-pneumococcal vaccine to adults at risk would generate a return of around 29 million euros.
Conclusion: In both cases, offering anti-pneumococcal 13-valent vaccine was proven to be a helpful
political health strategy, not only in consideration of a reduction of cases but also in view of
the favourable economic impacts.